RadNet, Inc. (RDNT) SEC Filings & Earnings Calls
EquiReason read 16 RadNet, Inc. SEC filings in the last 12 months. Latest: 8-K on 2026-08-14 — RadNet filed prospectus supplement to register 34,069 shares for resale by See-Mode sellers as milestone consideration; no new capital raise for company..
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 5.5B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
14 Aug 20268-K · 8.01RadNet filed prospectus supplement to register 34,069 shares for resale by See-Mode sellers as milestone consideration; no new capital raise for company.open
Figures in the filing · each found in the filing text
| shares registered for resale · Q3-2026 | 34,069 |
10 Aug 202610-QRadNet reported Q2 2026 revenue of $622.7M, up 25% YoY, and net income attributable to common stockholders of $7.5M, down 48% YoY.earningsopen
Figures in the filing · each found in the filing text
| Total service revenue · Q2-2026 | $623M | +25% y/y |
| Net income (loss) attributable to RadNet, Inc. · Q2-2026 | $8M | -48% y/y |
| Net cash provided by operating activities · H1-2026 | $173M | +7% y/y |
| Free cash flow · H1-2026 | $47M |
Risks flagged
Reimbursement Risk
“Revenue is dependent on contracts with third-party payors including Medicare and Medicaid; changes in reimbursement rates could impact revenue.”
Acquisition Integration Risk
“Acquisition-related costs totaled $10.1M in H1 2026, up from $3.0M in H1 2025, indicating significant M&A activity.”
Leverage Risk
“Notes payable increased to $1.33B from $1.09B at year-end 2025, and interest expense was $18.2M in Q2 2026.”
10 Aug 20268-K · 2.02RadNet reported record quarterly revenue of $622.7M (+25.0% YoY) and record Adjusted EBITDA of $99.7M (+22.7%). Raised FY2026 Imaging Center guidance for Revenue, Adjusted EBITDA, and Free Cash Flow. Digital Health ARR grew 97.2% YoY to $10open
Figures in the filing · each found in the filing text
| Total Company Revenue · Q2-2026 | $623M | +25% y/y |
| Digital Health Revenue · Digital Health · Q2-2026 | $32M | +57% y/y |
| Annual Recurring Revenue (ARR) · Digital Health · Q2-2026 | $106M | +97% y/y |
| Total Company Adjusted EBITDA · Q2-2026 | $100M | +23% y/y |
| Digital Health Adjusted EBITDA · Digital Health · Q2-2026 | $3M | -26% y/y |
| Imaging Center Segment Adjusted EBITDA Margin · Imaging Center · Q2-2026 | 16.1% | |
| Adjusted Earnings · Q2-2026 | $23M | -10% y/y |
| Adjusted Earnings Per Share · Q2-2026 | $0.29 | -15% y/y |
| Advanced Imaging Mix · Imaging Center · Q2-2026 | 29.9% | |
| Aggregate Advanced Imaging Procedural Volumes Growth · Imaging Center · Q2-2026 | 21.2% |
Guidance
FY2026 Imaging Center guidance raised for Revenue, Adjusted EBITDA, and Free Cash Flow; Digital Health guidance reaffirmed
Strong Q2 results with record revenue and EBITDA; guidance raised for Imaging Center segment; Digital Health ARR nearly doubled.
Risks flagged
Digital Health segment profitability negative due to investment; may pressure near-term margins.
“Digital Health Adjusted EBITDA $2.5M vs $3.4M prior year, decline due to infrastructure investments.”
Guidance raise may set high expectations; execution risk on growth and margin expansion.
“Guidance raised for Imaging Center; Digital Health guidance reaffirmed.”
10 Jun 20268-K · 1.01, 2.03, 7.01RadNet secured a $250M incremental term loan, reduced interest rate by 0.25%, and lowered cost on undrawn revolver. Proceeds for acquisitions, organic expansion, and partnerships. CFO positive tone.open
Risks flagged
Increased leverage from additional $250M debt; quarterly principal payments increase from $2.4M to $3.1M.
“Borrower will be required to make quarterly payments of principal on the Term Loan in the amount of approximately $3.1 million compared to approximately $2.4 million prior.”
11 May 202610-QTotal service revenue $576M (+22% y/y); Net loss attributable to RadNet $-33M (-12% y/y); Operating cash flow $79M (+90% y/y)open
Figures in the filing · each found in the filing text
| Total service revenue · Q1-2026 | $576M | +22% y/y |
| Net loss attributable to RadNet · Q1-2026 | $-33M | -12% y/y |
| Operating cash flow · Q1-2026 | $79M | +90% y/y |
| Free cash flow · Q1-2026 | $9M | -100% y/y |
Risks flagged
Acquisition integration risk
“Goodwill increased to $1,094.7 million from $907.7 million due to acquisitions.”
Operating loss persists
“Loss from operations $23,903 thousand for Q1 2026.”
11 May 20268-K · 2.02Total Company Revenue $576M (+22% y/y); Digital Health Revenue $29M (+52% y/y); Annual Recurring Revenue (ARR) $97M (+95% y/y); Guidance: Increased 2026 Imaging Center guidance for Revenue, Adjusted EBITDA and Free Cash Flow; reaffirmed allearningsopen
Figures in the filing · each found in the filing text
| Total Company Revenue · Q1-2026 | $576M | +22% y/y |
| Digital Health Revenue · Digital Health · Q1-2026 | $29M | +52% y/y |
| Annual Recurring Revenue (ARR) · Digital Health · Q1-2026 | $97M | +95% y/y |
| Total Company Adjusted EBITDA · Q1-2026 | $63M | +36% y/y |
| Digital Health Adjusted EBITDA · Digital Health · Q1-2026 | $1M | -65% y/y |
| Aggregate advanced imaging procedural volumes growth · Imaging Center · Q1-2026 | 19.7% | |
| Same-center advanced imaging procedural volumes growth · Imaging Center · Q1-2026 | 8.2% | |
| Cash balance · Q1-2026 | $455M |
Guidance
Increased 2026 Imaging Center guidance for Revenue, Adjusted EBITDA and Free Cash Flow; reaffirmed all Digital Health guidance ranges
Raised full-year 2026 Imaging Center guidance for Revenue, Adjusted EBITDA and Free Cash Flow; Digital Health guidance reaffirmed; strong Q1 performance and continued momentum into early May.
Risks flagged
Digital Health segment profitability declined due to intentional infrastructure investments
“Digital Health reportable segment Adjusted EBITDA decreased to $1.3 million in the first quarter of 2026 from $3.7 million in the first quarter of 2025 resulting from continued intentional infrastructure investments”
Weather impact in Q1 reduced revenue and EBITDA by an estimated $13M and $9M respectively
“After being impacted by severe winter weather conditions in the Northeast during January and February which reduced Revenue and Adjusted EBITDA by an estimated $13 million and $9 million, respectively” · word for word
20 Apr 2026DEF 14ARadNet filed its proxy statement (DEF 14A) for the 2026 Annual Meeting of Stockholders, disclosing executive compensation details, the incentive map, and a proposal to amend and restate the Equity Incentive Plan.open
Figures in the filing · each found in the filing text
| Total Revenue · FY2025 | $2.04B | +12% y/y |
| Adjusted EBITDA · FY2025 | $300M | |
| Net Income · FY2025 | $-19M | |
| Total Shareholder Return · FY2025 | $364.59 | |
| Peer Group Total Shareholder Return · FY2025 | $111.51 | |
| Number of Imaging Centers · 2025-12-31 | 418 | |
| CEO Total Compensation · FY2025 | $12M | |
| CEO Base Salary · FY2025 | $3M | |
| CEO Equity Grant Value · FY2025 | $9M | |
| CEO Cash Bonus · FY2025 | $0.00 |
2 Mar 202610-KTotal centers owned or managed 418 (+5% y/y); MRI equipment count 420 (+10% y/y); CT equipment count 230 (+4% y/y)open
Figures in the filing · each found in the filing text
| Total centers owned or managed · FY2025 | 418 | +5% y/y |
| MRI equipment count · FY2025 | 420 | +10% y/y |
| CT equipment count · FY2025 | 230 | +5% y/y |
| Mammography equipment count · FY2025 | 455 | +7% y/y |
| Ultrasound equipment count · FY2025 | 976 | +8% y/y |
| Total equipment count · FY2025 | 2,703 | +6% y/y |
| FDA clearances · Digital Health · FY2025 | 22 | |
| CE marks · Digital Health · FY2025 | 15 | |
| Digital Health customers · Digital Health · FY2025 | 2,000 | |
| Medicare revenue percentage · FY2025 | 23.4% |
Risks flagged
Medicare Reimbursement Reduction
“On October 30, 2025, CMS released the calendar year 2026 Medicare Physician Fee Schedule final rule, which governs Medicare payment for Radnet's services in CY 2026. Medicare payment and coverage policies in the final rule could result in reimbursement reductions or reduced volume of diagnostic imaging services at our imaging centers.” · word for word
Labor Cost Increase
“In 2024, California mandated minimum wage increases for certain industries, including ours. As a result, we experienced increased compensation costs for certain of our employees and vendors beginning in 2025.” · word for word
Regulatory Compliance Cost
“The healthcare industry is highly regulated, and changes in the regulatory environment could significantly affect our operations in the future.” · word for word
2 Mar 20268-K · 7.01Purchase price 230,000,000; Gleamer expected ARR 2026 $30M; Gleamer ARR CAGR 2022-2025 90open
Figures in the filing · each found in the filing text
| Purchase price | $230M | |
| Gleamer expected ARR 2026 · Digital Health · FY2026 | $30M | |
| Gleamer ARR CAGR 2022-2025 · Digital Health · 2022-2025 | 90.0% | |
| Customer contracts · Digital Health | 700 |
Risks flagged
Integration risk and execution of cross-border acquisition.
“Acquisition of French company; integration of Gleamer's 130+ professionals and technology into DeepHealth.”
Contingent payment of €15M subject to milestone achievement.
“Contingent payment of approximately €15.0 million in cash, subject to completion or satisfaction of certain milestones by Gleamer.” · word for word
2 Mar 20268-K · 2.02Total Company Revenue $548M (+15% y/y); Total Company Adjusted EBITDA $88M (+17% y/y); Digital Health Revenue $28M (+48% y/y); Guidance: Imaging Center Revenue growth 17-19%; Adjusted EBITDA growth 18-22%; Free Cash Flow growth 29-41%; Digiearningsopen
Figures in the filing · each found in the filing text
| Total Company Revenue · Q4-2025 | $548M | +15% y/y |
| Total Company Adjusted EBITDA · Q4-2025 | $88M | +17% y/y |
| Digital Health Revenue · Digital Health · Q4-2025 | $28M | +48% y/y |
| Digital Health Adjusted EBITDA · Digital Health · Q4-2025 | $5M | +9% y/y |
| Adjusted EBITDA margin · Q4-2025 | 16.0% | |
| Adjusted Earnings Per Share · Q4-2025 | $0.23 | |
| Advanced imaging procedural volume growth (aggregate) · Q4-2025 | 14.1% | |
| Same-center advanced imaging procedural volume growth · Q4-2025 | 9.6% |
Guidance
Imaging Center Revenue growth 17-19%; Adjusted EBITDA growth 18-22%; Free Cash Flow growth 29-41%; Digital Health Revenue growth 46-56%
Strong 2026 guidance across all segments with accelerating revenue growth, margin expansion, and robust free cash flow growth.
Risks flagged
One-time items impacting net income including severance, impairment, acquisition costs, and R&D expenses.
“Unusual or one-time items: $531K severance, $233K impairment, $788K pre-opening leases, $2.3M acquisition costs, $6.5M loss on sale of equipment, $6.3M non-capitalized R&D.”
30 Jan 20268-K · 8.01Disclosed a material event under other events (litigation, recall, contract loss, or major announcement); filed financial statements and exhibits with this reportopen
Risks flagged
Potential dilution from share resale, but limited magnitude.
“190,924 shares registered for resale, representing a small fraction of outstanding shares.”
4 Dec 20258-K · 8.01Disclosed a material event under other events (litigation, recall, contract loss, or major announcement); filed financial statements and exhibits with this reportopen
Risks flagged
Potential overhang from resale shares, but amount is immaterial (73,567 shares).
“up to 73,567 shares of the Company’s common stock” · word for word
10 Nov 20258-K · 2.02Revenue $523M (+13% y/y); Adjusted EBITDA $85M (+15% y/y); Digital Health Revenue $25M (+52% y/y); Guidance: Increased Imaging Center Revenue and Adjusted EBITDA ranges; raised Digital Health Revenue guidanceearningsopen
Figures in the filing · each found in the filing text
| Revenue · Q3-2025 | $523M | +13% y/y |
| Adjusted EBITDA · Q3-2025 | $85M | +15% y/y |
| Digital Health Revenue · Digital Health · Q3-2025 | $25M | +52% y/y |
| Digital Health Adjusted EBITDA · Digital Health · Q3-2025 | $4M | +7% y/y |
| Adjusted Diluted EPS · Q3-2025 | $0.20 | +11% y/y |
| Aggregate advanced imaging procedural volume growth · Q3-2025 | 13.0% | |
| Same-center advanced imaging procedural volume growth · Q3-2025 | 9.9% | |
| Cash balance · Q3-2025 | $805M | |
| Net Debt to Adjusted EBITDA ratio · Q3-2025 | $1.00 |
Guidance
Increased Imaging Center Revenue and Adjusted EBITDA ranges; raised Digital Health Revenue guidance
Raised full-year guidance for Imaging Center Revenue and Adjusted EBITDA and Digital Health Revenue.
Risks flagged
One-time items impacting net income; adjusted metrics provide clearer picture.
“There were a number of unusual or one-time items impacting the third quarter including: $2.6 million of non-cash loss from interest rate swaps; $1.4 million in severance expense; $621,000 expense related to leases for de novo facilities; $5.5 million of non-capitalized R&D expenses; $2.1 million of acquisition transaction costs; and $2.8 million of lease aba” · word for word
10 Nov 202510-QRadNet reported Q3 2025 revenue of $522.9M (+13.4% YoY) and net income attributable to common stockholders of $5.4M (+68.8% YoY).earningsopen
Figures in the filing · each found in the filing text
| Total service revenue · Q3-2025 | $523M | +13% y/y |
| Net income (loss) attributable to RadNet, Inc. · Q3-2025 | $5M | +69% y/y |
| Net cash provided by operating activities · 9M-2025 | $215M | +13% y/y |
| Free cash flow · 9M-2025 | $52M |
Risks flagged
Lease abandonment charges
“During the nine months ended September 30, 2025, we closed several imaging centers with lower utilization and recognized lease abandonment charges of approximately $8.3 million.” · word for word
Acquisition integration risk
“Acquisition-related costs totaled approximately $2.1 million and $5.1 million for the three and nine ended September 30, 2025, respectively.”
RadNet, Inc. — questions
- What did RadNet, Inc. file recently?
- 16 SEC filings in the last 12 months. Latest: 8-K on 2026-08-14 — RadNet filed prospectus supplement to register 34,069 shares for resale by See-Mode sellers as milestone consideration; no new capital raise for company.
Every figure on this page comes from RadNet, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.